Suppr超能文献

轮状病毒疫苗接种在非洲实施后,儿童腹泻住院和死亡人数的估计减少量。

Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa.

机构信息

a Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , USA.

b World Health Organization , Regional Office for Africa , Brazzaville , Republic of Congo.

出版信息

Expert Rev Vaccines. 2017 Oct;16(10):987-995. doi: 10.1080/14760584.2017.1371595. Epub 2017 Sep 4.

Abstract

Rotavirus is the leading cause of hospitalizations and deaths from diarrhea. 33 African countries had introduced rotavirus vaccines by 2016. We estimate reductions in rotavirus hospitalizations and deaths for countries using rotavirus vaccination in national immunization programs and the potential of vaccine introduction across the continent. Areas covered: Regional rotavirus burden data were reviewed to calculate hospitalization rates, and applied to under-5 population to estimate baseline hospitalizations. Rotavirus mortality was based on 2013 WHO estimates. Regional pre-licensure vaccine efficacy and post-introduction vaccine effectiveness studies were used to estimate summary effectiveness, and vaccine coverage was applied to calculate prevented hospitalizations and deaths. Uncertainties around input parameters were propagated using boot-strapping simulations. In 29 African countries that introduced rotavirus vaccination prior to end 2014, 134,714 (IQR 112,321-154,654) hospitalizations and 20,986 (IQR 18,924-22,822) deaths were prevented in 2016. If all African countries had introduced rotavirus vaccines at benchmark immunization coverage, 273,619 (47%) (IQR 227,260-318,102) hospitalizations and 47,741 (39%) (IQR 42,822-52,462) deaths would have been prevented. Expert commentary: Rotavirus vaccination has substantially reduced hospitalizations and deaths in Africa; further reductions are anticipated as additional countries implement vaccination. These estimates bolster wider introduction and continued support of rotavirus vaccination programs.

摘要

轮状病毒是导致腹泻住院和死亡的主要原因。截至 2016 年,33 个非洲国家已引入轮状病毒疫苗。我们估计,在国家免疫规划中使用轮状病毒疫苗的国家,轮状病毒住院和死亡人数将会减少,并且疫苗在整个非洲大陆的推广潜力。涵盖领域:审查区域轮状病毒负担数据以计算住院率,并将其应用于 5 岁以下人群以估计基线住院人数。轮状病毒死亡率基于 2013 年世卫组织的估计。区域疫苗上市前效力和疫苗引入后效力研究用于估计综合效力,并应用疫苗覆盖率计算预防住院和死亡人数。使用自举模拟法传播输入参数的不确定性。在 29 个非洲国家中,29 个国家在 2014 年底前引入了轮状病毒疫苗,2016 年预防了 134714 例(IQR112321-154654)住院和 20986 例(IQR18924-22822)死亡。如果所有非洲国家都按照基准免疫覆盖率引入轮状病毒疫苗,那么 273619 例(47%)(IQR227260-318102)住院和 47741 例(39%)(IQR42822-52462)死亡将被预防。专家评论:轮状病毒疫苗已大大减少了非洲的住院和死亡人数;随着更多国家实施疫苗接种,预计还会进一步减少。这些估计结果支持更广泛地推广和继续支持轮状病毒疫苗接种计划。

相似文献

引用本文的文献

4
Antimicrobial resistance containment in Africa: Moving beyond surveillance.非洲的抗菌药物耐药性控制:超越监测
Biosaf Health. 2023 Dec 29;6(1):50-58. doi: 10.1016/j.bsheal.2023.12.003. eCollection 2024 Feb.

本文引用的文献

6
Options for improving effectiveness of rotavirus vaccines in developing countries.提高发展中国家轮状病毒疫苗效力的方法
Hum Vaccin Immunother. 2017 Apr 3;13(4):921-927. doi: 10.1080/21645515.2016.1252493. Epub 2016 Nov 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验